open access

Vol 81, No 4 (2013)
ORIGINAL PAPERS
Submitted: 2013-06-07
Accepted: 2013-06-07
Get Citation

The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer — a potential application in classification for therapy

Marcin Nicoś, Paweł Krawczyk, Radosław Mlak, Marek Sawicki, Bożena Jarosz, Tomasz Powrózek, Piotr Milanowski, Tomasz Trojanowski, Janusz Milanowski
Pneumonol Alergol Pol 2013;81(4):294-297.

open access

Vol 81, No 4 (2013)
ORIGINAL PAPERS
Submitted: 2013-06-07
Accepted: 2013-06-07

Abstract

INTRODUCTION: HER2 (ErbB2/neu) is a member of the ErbB family of four structurally related receptors of tyrosine kinase activity. Overexpression of ErbB-1 (EGFR) and HER2 is found in many human cancers, but the presence of these genes mutations determines the effectiveness of EGFR and HER2 tyrosine kinase inhibitors in the therapy of non-small cell lung cancer (NSCLC).

MATERIAL AND METHODS: To search for insertions of the HER2 gene in exon 20 in 150 brain metastases of non-small cell lung cancer patients, we used a PCR technique based on analysis of amplified DNA fragment lengths. We also compared the HER2 mutational status with clinicopathologic features and the presence of EGFR and BRAF mutations.

RESULTS: HER2 mutation was present in one male, non-smoking patient with low differentiated adenocarcinoma (0.67% of all patients and 1.5% of patients with adenocarcinoma). The mutations of EGFR and BRAF genes were not found in HER2-mutated patient.

CONCLUSIONS: The literature data suggests that patients with HER2 mutations may be sensitive to tyrosine kinase inhibitors of both EGFR and HER2 receptors (e.g. afatinib). Therefore, the identification of new driver mutations in NSCLC can improve the quality of patient care by enabling the use of correct molecularly targeted therapies.

Abstract

INTRODUCTION: HER2 (ErbB2/neu) is a member of the ErbB family of four structurally related receptors of tyrosine kinase activity. Overexpression of ErbB-1 (EGFR) and HER2 is found in many human cancers, but the presence of these genes mutations determines the effectiveness of EGFR and HER2 tyrosine kinase inhibitors in the therapy of non-small cell lung cancer (NSCLC).

MATERIAL AND METHODS: To search for insertions of the HER2 gene in exon 20 in 150 brain metastases of non-small cell lung cancer patients, we used a PCR technique based on analysis of amplified DNA fragment lengths. We also compared the HER2 mutational status with clinicopathologic features and the presence of EGFR and BRAF mutations.

RESULTS: HER2 mutation was present in one male, non-smoking patient with low differentiated adenocarcinoma (0.67% of all patients and 1.5% of patients with adenocarcinoma). The mutations of EGFR and BRAF genes were not found in HER2-mutated patient.

CONCLUSIONS: The literature data suggests that patients with HER2 mutations may be sensitive to tyrosine kinase inhibitors of both EGFR and HER2 receptors (e.g. afatinib). Therefore, the identification of new driver mutations in NSCLC can improve the quality of patient care by enabling the use of correct molecularly targeted therapies.

Get Citation

Keywords

non-small cell lung cancer, brain metastases, HER2 mutation

About this article
Title

The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer — a potential application in classification for therapy

Journal

Advances in Respiratory Medicine

Issue

Vol 81, No 4 (2013)

Pages

294-297

Bibliographic record

Pneumonol Alergol Pol 2013;81(4):294-297.

Keywords

non-small cell lung cancer
brain metastases
HER2 mutation

Authors

Marcin Nicoś
Paweł Krawczyk
Radosław Mlak
Marek Sawicki
Bożena Jarosz
Tomasz Powrózek
Piotr Milanowski
Tomasz Trojanowski
Janusz Milanowski

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl